Abstract
BackgroundObesity is characterized by the accumulation of fat in the liver and other tissues, leading to insulin resistance. We have previously shown that a specific inhibitor of glucosylceramide synthase, which inhibits the initial step in the synthesis of glycosphingolipids (GSLs), improved glucose metabolism and decreased hepatic steatosis in both ob/ob and diet-induced obese (DIO) mice. Here we have determined in the DIO mouse model the efficacy of a related small molecule compound, Genz-112638, which is currently being evaluated clinically for the treatment of Gaucher disease, a lysosomal storage disorder.Methodology/Principal FindingsDIO mice were treated with the Genz-112638 for 12 to 16 weeks by daily oral gavage. Genz-112638 lowered HbA1c levels and increased glucose tolerance. Whole body adiposity was not affected in normal mice, but decreased in drug-treated obese mice. Drug treatment also significantly lowered liver triglyceride levels and reduced the development of hepatic steatosis. We performed hyperinsulinemic-euglycemic clamps on the DIO mice treated with Genz-112638 and showed that insulin-mediated suppression of hepatic glucose production increased significantly compared to the placebo treated mice, indicating a marked improvement in hepatic insulin sensitivity.Conclusions/SignificanceThese results indicate that GSL inhibition in obese mice primarily results in an increase in insulin action in the liver, and suggests that GSLs may have an important role in hepatic insulin resistance in conditions of obesity.
Highlights
The accumulation of visceral fat in obesity instigates several pathological changes, including chronic low-grade inflammation, steatosis, and insulin resistance [1,2,3]
Conclusions/Significance: These results indicate that GSL inhibition in obese mice primarily results in an increase in insulin action in the liver, and suggests that GSLs may have an important role in hepatic insulin resistance in conditions of obesity
We have previously shown that a small molecule inhibitor of glucosylceramide synthase (GCS), the initial and rate-limiting enzyme involved in the biosynthesis of gangliosides and other glycosphingolipids (GSLs), improved glycemic control, decreased insulin resistance, and inhibited the development of hepatic steatosis in several animal models of type 2 diabetes [9,10]
Summary
The accumulation of visceral fat in obesity instigates several pathological changes, including chronic low-grade inflammation, steatosis, and insulin resistance [1,2,3]. These alterations are closely associated with the development of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) [4,5]. In obese and diabetic patients, hepatic steatosis results in a failure of insulin action and leads to excessive hepatic glucose production (HGP) and fasting hyperglycemia [6]. Obesity is characterized by the accumulation of fat in the liver and other tissues, leading to insulin resistance. We have determined in the DIO mouse model the efficacy of a related small molecule compound, Genz-112638, which is currently being evaluated clinically for the treatment of Gaucher disease, a lysosomal storage disorder
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
